James G. Ryall

James G. Ryall

Auto-generated profile, based on publicly available information

James G. Ryall

Stem Cell Metabolism & Regenerative Medicine Group, Basic & Clinical Myology Laboratory, The University of Melbourne, Melbourne, VIC 3010, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Cell Stem Cell
Verified
Journal Article
Closed access
JRJames G. Ryall
James G. Ryall
SDStefania Dell’oRso
Stefania Dell’oRso
ADAssia Derfoul
Assia Derfoul
AJAster Juan
Aster Juan
HZHossein Zare
Hossein Zare
VSVittorio Sartorelli
Vittorio Sartorelli

15 September 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RMRichard J. Mills
Richard J. Mills
DTDrew M. Titmarsh
Drew M. Titmarsh
XKXaver König
Xaver König
BPBenjamin L. Parker
Benjamin L. Parker
JRJames G. Ryall
James G. Ryall
JHJames E. Hudson
James E. Hudson
Significance: Engineered cardiac muscle can be used to promote the structural and functional maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs). However, previous studies have not yet produced cardiac tissues with metabolic and proliferative maturation. Here, we develop a 96-well screening platform and screen for cardiac maturation conditions in engineered cardiac muscle. We found that simulating the postnatal switch in metabolic substrates from carbohydrates to fatty acids promoted a switch in metabolism, DNA damage response, and cell cycle arrest in hPSC-CM. Our study shows that this mechanism can be harnessed to enhance the maturation of human hPSC-CM and cardiac tissues, which has major implications for stem cell sciences, drug discovery, and regenerative medicine.

1 April 2008 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
GLGordon S Lynch
Gordon S Lynch
JRJames G. Ryall
James G. Ryall
The importance of β-adrenergic signaling in the heart has been well documented, but it is only more recently that we have begun to understand the importance of this signaling pathway in skeletal muscle. There is considerable evidence regarding the stimulation of the β-adrenergic system with β-adrenoceptor agonists (β-agonists). Although traditionally used for treating bronchospasm, it became apparent that some β-agonists could increase skeletal muscle mass and decrease body fat. These so-called “repartitioning effects” proved desirable for the livestock industry trying to improve feed efficiency and meat quality. Studying β-agonist effects on skeletal muscle has identified potential therapeutic applications for muscle wasting conditions such as sarcopenia, cancer cachexia, denervation, and neuromuscular diseases, aiming to attenuate (or potentially reverse) the muscle wasting and associated muscle weakness, and to enhance muscle growth and repair after injury. Some undesirable cardiovascular side effects of β-agonists have so far limited their therapeutic potential. This review describes the physiological significance of β-adrenergic signaling in skeletal muscle and examines the effects of β-agonists on skeletal muscle structure and function. In addition, we examine the proposed beneficial effects of β-agonist administration on skeletal muscle along with some of the less desirable cardiovascular effects. Understanding β-adrenergic signaling in skeletal muscle is important for identifying new therapeutic targets and identifying novel approaches to attenuate the muscle wasting concomitant with many diseases.

26 February 2008 in Biogerontology
Verified
Journal Article
Closed access
PDF file
JRJames G. Ryall
James G. Ryall
JSJonathan D. Schertzer
Jonathan D. Schertzer
GLGordon S Lynch
Gordon S Lynch

1 December 2015 in Cell Stem Cell
Verified
Journal Article
Closed access
JRJames G. Ryall
James G. Ryall
TCTim Cliff
Tim Cliff
SDStephen Dalton
Stephen Dalton
VSVittorio Sartorelli
Vittorio Sartorelli

15 April 2011 in Genes & Development
Verified
Journal Article
Closed access
PDF file
AJAster H. Juan
Aster H. Juan
ADAssia Derfoul
Assia Derfoul
XFXuesong Feng
Xuesong Feng
JRJames G. Ryall
James G. Ryall
SDStefania Dell'ORso
Stefania Dell'ORso
VSVittorio Sartorelli
Vittorio Sartorelli
Satellite cells (SCs) sustain muscle growth and empower adult skeletal muscle with vigorous regenerative abilities. Here, we report that EZH2, the enzymatic subunit of the Polycomb-repressive complex 2 (PRC2), is expressed in both Pax7+/Myf5− stem cells and Pax7+/Myf5+ committed myogenic precursors and is required for homeostasis of the adult SC pool. Mice with conditional ablation of Ezh2 in SCs have fewer muscle postnatal Pax7+ cells and reduced muscle mass and fail to appropriately regenerate. These defects are associated with impaired SC proliferation and derepression of genes expressed in nonmuscle cell lineages. Thus, EZH2 controls self-renewal and proliferation, and maintains an appropriate transcriptional program in SCs.